drugset / Trial / NCT00260611
Study of Oxaliplatin and Taxotere in Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective for this study is to evaluate PSA response rates (response will be defined as a \> 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
Timeline
- Start
- 2004-11
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |